糖皮质激素不同给药方式的药效学及药动学研究进展
作者：郑妮;郑晶晶;陈新;
Author：
收稿日期： 年卷（期）页码：2011,26(04):-391-394
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：哮喘;不同给药方式;糖皮质激素;吸入型;综述
Key words：
基金项目：
中文摘要
哮喘的治疗目标是达到并维持哮喘临床控制,糖皮质激素主要通过抗炎作用维持哮喘的临床控制。本文综述了近年来哮喘抗炎治疗的最新进展,比较哮喘治疗中糖皮质激素不同给药方式的药效学及药动学差异,为吸入型糖皮质激素治疗哮喘的安全性、有效性提供根据。
参考文献
[1]Nair P.Early interventions with inhaled corticosteroids in asthma:benefits and risks[J].Curr Opin Pulm Med,2011,17(1):12-15.
[2]Davis SQ,Krishnan JA,Lee K,et al.Effect of a community-wide asthma intervention on appropriate use of inhaled corticoste-roids[J].J Urban Health,2011,88(Suppl 1):144-155.
[3]Grzanka A,Jarzab J.Difficulties in determining of the equivalentdoses of inhaled glucocorticoids[J].Pol Merkur Lekarski,2010,28(164):134-137.
[4]Cerasoli F Jr.Developing the ideal inhaled corticosteroid[J].Chest,2006,130(1 Suppl):54S-64S.
[5]Allen DB,Bielory L,Derendorf H,et al.Inhaled corticosteroids:past lessons and future issues[J].J Allergy Clin Immunol,2003,112(3):1-40.
[6]Leach CL,Bet hke TD,Boudreau RJ,et al.Two-dimensional andthree-dimensional imaging show ciclesonide has high lung depo-sition and peripheral dist ribution:a nonrandomized study inhealthy volunteers[J].J Aerosol Med,2006,19(2):117-126.
[7]Newman S,Salmon A,Nave R,et al.High lung deposition of99mTc-labeled ciclesonide administered via HFA-MDI to pa-tients with asthma[J].Respir Med,2006,100(3):375-384.
[8]Rohatagi S,Luo Y,Shen L,et al.Protein binding and its poten-tial for eliciting minimal systemic side effects with a novel inhaledcorticosteroid,ciclesonide[J].Am J Ther,2005,12(3):201-209.
[9]Leach CL,Davidson PJ,Hasselquist BE.Lung deposition ofhydrofluoroalkane-134a beclomethasone is greater than that ofchlorofluorocarbon fluticasone and chlorofluorocarbon beclometha-sone:a cross-over study in healthy volunteers[J].Chest,2002,122(2):510-516.
[10]Stephen B,Shrewsbury,Andrew P,et al.Pharmacokinetics of anovel submicron budesonide dispersion for nebulized delivery inasthma[J].Int J Pharm,2009,365(1-2):12-17.
[11]Murphy K,Noonan M,Silkoff PE,et al.A 12-week,multi-center,randomized,partially blinded,active-controlled,paral-lel-group study of budesonide inhalation suspension in adoles-cents and adults with moderate to severe persistent asthma previ-ously receiving inhaled corticosteroids with a metered-dose or drypowder inhaler[J].Clin Thr,2007,29(6):1013-1026.
[12]O'Connor BJ,Kilfeather S,Cheung D,et al.Efficacy and safety ofciclesonide in patients with severe asthma:a 12-week,double-blind,randomized,parallel-group study with long-term(1-year)follow-up[J].Expert Opin Pharmacother,2010,11(17):2791-2803.
[13]Nave R,Fisher R,Zech K.In Vitro metabolism of ciclesonide inhuman lung and liver precision-cut tissue slices[J].BiopharmDrug Dispos,2006,27(4):197-207.
[14]Meijer RJ,Postma DS,Kauffman HF,et al.Accuracy of eosinophilsand eosinophil cationic protein to predict steroid improvement inasthma[J].Clin Exp Allergy,2002,32(7):1096-1103.
[15]Mikhak Z.Dose-response studies of fluticasone propionate andbudesonide:classification based on asthma severity[J].AllergyAsthma Proc,2006,27(5):402-411.
[16]Czock D,Keller F,Rasche FM,et al.Pharmacokinetics and phar-macodynamics of systemically administered glucocorticoids[J].Clin Pharmacokinet,2005,44(1):61-98.
[17]Haasler I,Buhl R,Taube C.Asthma:new insights and advances intreatment[J].Dtsch Med Wochenschr,2011,136(5):198-200.
[18]Pauwels RA.Similarities and differences in asthma and chronicobstructive pulmonary disease exacerbations[J].Proc Am ThoracSoc,2004,1(2):73-76.
[19]Burge PS,Robertson A.Exercise-induced asthma,respiratoryand allergic disorders in elite athletes[J].Allergy,2008,63(8):1084.
[20]Stanford RH,Yancey SW,Stempel DA.Asthma control differencesbetween inhaled corticosteroids likely related to differences in pa-tient severity[J].J Allergy Clin Immunol,2011,127(3):835.
[21]Korenblat PE.Ciclesonide and the treatment of asthma expert[J].Opin Pharmacother,2010,11(3):463-479.
[22]Adcock IM,Caramori G,Chung KF.New targets for drug develop-ment in asthma[J].Lancet,2008,372(9643):1073-1087.
【关闭】
